LEADER 03731nam  2200589Ia 450 
001 9910818706103321
005 20230417210405.0
035   $a(CKB)1000000000450597
035   $a(EBL)3377805
035   $a(SSID)ssj0000181063
035   $a(PQKBManifestationID)11165476
035   $a(PQKBTitleCode)TC0000181063
035   $a(PQKBWorkID)10168146
035   $a(PQKB)10044563
035   $a(OCoLC)560535074
035   $a(MiAaPQ)EBC3377805
035   $a(EXLCZ)991000000000450597
100   $a20050324d1999      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aInternational benchmarking of US immunology research /$fPanel on International Benchmarking of US Immunology Research, Committee on Science, Engineering, and Public Policy, National Academy of Sciences, National Academy of Engineering, Institute of Medicine
210   $aWashington, DC $cNational Academy Press$d1999
215   $a1 online resource (60 pages) $cillustrations
300   $a"Prepublication copy."
311 0 $a0-309-58443-4 
320   $aIncludes bibliographical references.
327   $a""INTERNATIONAL BENCHMARKING OF US IMMUNOLOGY RESEARCH""; ""Copyright""; ""PREFACE""; ""CONTENTS""; ""EXECUTIVE SUMMARY""; ""1 INTRODUCTION""; ""1.1 HOW IMPORTANT IS IT FOR THE UNITED STATES TO LEAD IN IMMUNOLOGY RESEARCH?""; ""1.2 WHAT IS IMMUNOLOGY?""; ""1.3 IMMUNOLOGY AS AN ACADEMIC DISCIPLINE""; ""1.4 WHAT IS THE INTERNATIONAL NATURE OF IMMUNOLOGY?""; ""1.5 WHAT ARE SOME CAVEATS?""; ""1.6 PANEL CHARGE AND RATIONALE""; ""2 BENCHMARKING RESULTS""; ""2.1 METHODS""; ""2.1.1 Reputation Survey""; ""2.1.2 Citation Analysis""; ""2.1.3 Journal Publication Analysis""; ""2.2 RESULTS""
327   $a""2.2.1 Reputation Survey"" ""2.2.2 Citation Analysis""; ""2.2.3 Journal Publication Analysis""; ""2.3 SUMMARY""; ""3 KEY FACTORS""; ""3.1 FUNDING""; ""3.2 HUMAN RESOURCES""; ""3.3 INFRASTRUCTURE""; ""3.4 BIOTECHNOLOGY AND PHARMACEUTICAL FIRMS""; ""3.5 THE CLINICAL TRIAL""; ""4 LIKELY FUTURE POSITION""; ""4.1 FUNDING AND RESOURCE LIMITATIONS""; ""4.2 INCREASED COMPETITION FROM EUROPE AND OTHER COUNTRIES""; ""4.3 CLINICAL IMMUNOLOGY AND THE SHIFT TOWARD HMOS""; ""4.4 TRAINING OF US STUDENTS""; ""5 SUMMARY AND CONCLUSIONS""
327   $a""5.1 THE UNITED STATES IS THE WORLD LEADER IN ALL THE MAJOR SUBFIELDS OF IMMUNOLOGY BUT IS ONLY AMONG THE WORLD LEADERS IN""""5.2 FLEXIBILITY TO PURSUE ORIGINAL AND INNOVATIVE RESEARCH IDEAS HAS ATTRACTED BOTH DOMESTIC AND INTERNATIONAL HUMAN""; ""5.3 INDUSTRIAL INTERESTS HAVE FOSTERED MANY STRIKING BREAKTHROUGHS IN IMMUNOLOGY""; ""5.4 A SCARCITY OF LARGE-SCALE CLINICAL TRIALS IN IMMUNOLOGY CAN BE ATTRIBUTED TO SHORTAGES OF FUNDING AND OF QUALIFIED""; ""5.5 SHIFTING FEDERAL AND INDUSTRY PRIORITIES, A POTENTIAL REDUCTION IN ACCESS TO DOMESTIC AND FOREIGN TALENT, AND THE""; ""REFERENCES""""APPENDIX PANEL AND STAFF BIOGRAPHICAL INFORMATION""; ""STAFF""
606   $aImmunology$xResearch
606   $aImmunity
606   $aImmunochemistry
606   $aImmunogenetics
606   $aBenchmarking (Management)
615  0$aImmunology$xResearch.
615  0$aImmunity.
615  0$aImmunochemistry.
615  0$aImmunogenetics.
615  0$aBenchmarking (Management)
676   $a616.079072
712 02$aPanel on International Benchmarking of US Immunology Research.
712 02$aCommittee on Science, Engineering, and Public Policy (U.S.)
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910818706103321
996   $aInternational benchmarking of US immunology research$94118625
997   $aUNINA